Comparison 2: NSAIDs compared with placebo

Source: Deussen AR, Ashwood P, Martis R, Stewart F, Grzeskowiak LE. Relief of pain due to uterine cramping/involution after birth. Cochrane Database Syst Rev. 2020;(10):CD004908.

Certainty assessment							№ of patients		Effect		Certainty (GRADE)	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	NSAIDs	Placebo	Relative (95% CI)	Absolute (95% CI)		
Adequate pain relief as reported by the woman												
11	randomized trials	serious [a]	not serious	serious [b]	not serious	none	466/649 (71.8%)	131/297 (44.1%)	**RR 1.66** (1.45 to 1.91)	**291 more per 1000** (from 198 more to 401 more)	⊕⊕◯◯ LOW	CRITICAL
Adequate pain relief as reported by the woman – aspirin 650 mg												
6	randomized trials	serious [a]	not serious	serious [b]	not serious	none	123/168 (73.2%)	60/114 (52.6%)	**RR 1.33** (1.09 to 1.61)	**174 more per 1000** (from 47 more to 321 more)	⊕⊕◯◯ LOW	CRITICAL
Adequate pain relief as reported by the woman – naproxen 275 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,d]	none	27/30 (90.0%)	9/15 (60.0%)	**RR 1.50** (0.98 to 2.31)	**300 more per 1000** (from 12 fewer to 786 more)	⊕◯◯◯ VERY LOW	CRITICAL
Adequate pain relief as reported by the woman – naproxen 300 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,d]	none	27/35 (77.1%)	9/17 (52.9%)	**RR 1.46** (0.90 to 2.36)	**244 more per 1000** (from 53 fewer to 720 more)	⊕◯◯◯ VERY LOW	CRITICAL
Adequate pain relief as reported by the woman – naproxen 550 mg												
1	randomized trials	serious [a]	not serious	serious [b]	serious [f]	none	23/30 (76.7%)	9/30 (30.0%)	**RR 2.56** (1.43 to 4.57)	**468 more per 1000** (from 129 more to 1000 more)	⊕◯◯◯ VERY LOW	CRITICAL
Adequate pain relief as reported by the woman – naproxen 600 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [d,e]	none	30/35 (85.7%)	10/18 (55.6%)	**RR 1.54** (1.00 to 2.38)	**300 more per 1000** (from 0 fewer to 767 more)	⊕◯◯◯ VERY LOW	CRITICAL

Certainty assessment							№ of patients		Effect		Certainty (GRADE)	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	NSAIDs	Placebo	Relative (95% CI)	Absolute (95% CI)		
Adequate pain relief as reported by the woman – flurbiprofen 50 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,d]	none	26/30 (86.7%)	10/16 (62.5%)	**RR 1.39** (0.93 to 2.08)	**244 more per 1000** (from 44 fewer to 675 more)	⊕◯◯◯ VERY LOW	CRITICAL
Adequate pain relief as reported by the woman – ketorolac 5 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,d]	none	26/30 (86.7%)	5/10 (50.0%)	**RR 1.73** (0.92 to 3.27)	**365 more per 1000** (from 40 fewer to 1000 more)	⊕◯◯◯ VERY LOW	CRITICAL
Adequate pain relief as reported by the woman – ketorolac 10 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,d]	none	25/30 (83.3%)	5/10 (50.0%)	**RR 1.67** (0.88 to 3.16)	**335 more per 1000** (from 60 fewer to 1000 more)	⊕◯◯◯ VERY LOW	CRITICAL
Adequate pain relief as reported by the woman – fenoprofen 12.5 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,,f]	none	12/27 (44.4%)	1/5 (20.0%)	**RR 2.22** (0.37 to 13.48)	**244 more per 1000** (from 126 fewer to 1000 more)	⊕◯◯◯ VERY LOW	CRITICAL
Adequate pain relief as reported by the woman – fenoprofen 25 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,,f]	none	15/27 (55.6%)	1/5 (20.0%)	**RR 2.78** (0.47 to 16.56)	**356 more per 1000** (from 106 fewer to 1000 more)	⊕◯◯◯ VERY LOW	CRITICAL
Adequate pain relief as reported by the woman – fenoprofen 50 mg												
2	randomized trials	serious [a]	not serious	serious [b]	serious [d]	none	33/54 (61.1%)	2/12 (16.7%)	**RR 3.72** (1.03 to 13.39)	**453 more per 1000** (from 5 more to 1000 more)	⊕◯◯◯ VERY LOW	CRITICAL

Certainty assessment							№ of patients		Effect		Certainty (GRADE)	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	NSAIDs	Placebo	Relative (95% CI)	Absolute (95% CI)		
Adequate pain relief as reported by the woman – fenoprofen 100 mg												
2	randomized trials	serious [a]	not serious	serious [b]	serious [d]	none	37/56 (66.1%)	3/13 (23.1%)	**RR 2.86** (1.04 to 7.89)	**429 more per 1000** (from 9 more to 1000 more)	⊕◯◯◯ VERY LOW	CRITICAL
Adequate pain relief as reported by the woman – fenoprofen 200 mg												
3	randomized trials	serious [a]	not serious	serious [b]	serious [d]	none	42/68 (61.8%)	5/25 (20.0%)	**RR 2.67** (1.15 to 6.23)	**334 more per 1000** (from 30 more to 1000 more)	⊕◯◯◯ VERY LOW	CRITICAL
Adequate pain relief as reported by the woman – fenoprofen 300 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	20/29 (69.0%)	2/7 (28.6%)	**RR 2.41** (0.73 to 7.99)	**403 more per 1000** (from 77 fewer to 1000 more)	⊕◯◯◯ VERY LOW	CRITICAL
Need for additional pain relief												
4	randomized trials	serious [a]	not serious	serious [b]	serious [g]	none	5/250 (2.0%)	24/125 (19.2%)	**RR 0.15** (0.07 to 0.33)	**163 fewer per 1000** (from 179 fewer to 129 fewer)	⊕◯◯◯ VERY LOW	CRITICAL
Need for additional pain relief – aspirin 650 mg												
2	randomized trials	serious [a]	not serious	serious [b]	serious [f]	none	1/60 (1.7%)	5/25 (20.0%)	**RR 0.11** (0.02 to 0.63)	**178 fewer per 1000** (from 196 fewer to 74 fewer)	⊕◯◯◯ VERY LOW	CRITICAL
Need for additional pain relief – ketorolac 5 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	1/30 (3.3%)	2/10 (20.0%)	**RR 0.17** (0.02 to 1.65)	**166 fewer per 1000** (from 196 fewer to 130 more)	⊕◯◯◯ VERY LOW	CRITICAL

Certainty assessment							№ of patients		Effect		Certainty (GRADE)	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	NSAIDs	Placebo	Relative (95% CI)	Absolute (95% CI)		
Need for additional pain relief – ketorolac 10 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	1/30 (3.3%)	2/10 (20.0%)	**RR 0.17** (0.02 to 1.65)	**166 fewer per 1000** (from 196 fewer to 130 more)	⊕◯◯◯ VERY LOW	CRITICAL
Need for additional pain relief – naproxen 275 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	0/30 (0.0%)	2/15 (13.3%)	**RR 0.10** (0.01 to 2.02)	**120 fewer per 1000** (from 132 fewer to 136 more)	⊕◯◯◯ VERY LOW	CRITICAL
Need for additional pain relief – naproxen 300 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	0/35 (0.0%)	2/17 (11.8%)	**RR 0.10** (0.01 to 1.98)	**106 fewer per 1000** (from 116 fewer to 115 more)	⊕◯◯◯ VERY LOW	CRITICAL
Need for additional pain relief – naproxen 600 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	0/35 (0.0%)	2/18 (11.1%)	**RR 0.11** (0.01 to 2.09)	**99 fewer per 1000** (from 110 fewer to 121 more)	⊕◯◯◯ VERY LOW	CRITICAL
Need for additional pain relief – naproxen 550 mg												
1	randomized trials	serious [a]	not serious	serious [b]	serious [f]	none	2/30 (6.7%)	9/30 (30.0%)	**RR 0.22** (0.05 to 0.94)	**234 fewer per 1000** (from 285 fewer to 18 fewer)	⊕◯◯◯ VERY LOW	CRITICAL
Maternal adverse effects												
8	randomized trials	serious [a]	not serious	serious [b]	serious [c]	none	92/372 (24.7%)	52/211 (24.6%)	**RR 1.05** (0.78 to 1.41)	**12 more per 1000** (from 54 fewer to 101 more)	⊕◯◯◯ VERY LOW	CRITICAL

Certainty assessment							№ of patients		Effect		Certainty (GRADE)	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	NSAIDs	Placebo	Relative (95% CI)	Absolute (95% CI)		
Maternal adverse effects – aspirin 650 mg												
5	randomized trials	serious [a]	not serious	serious [b]	very serious [c,d]	none	36/140 (25.7%)	24/83 (28.9%)	**RR 0.93** (0.58 to 1.47)	**20 fewer per 1000** (from 121 fewer to 136 more)	⨁◯◯◯ VERY LOW	CRITICAL
Maternal adverse effects – flurbiprofen 50 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	6/30 (20.0%)	3/16 (18.8%)	**RR 1.07** (0.31 to 3.71)	**13 more per 1000** (from 129 fewer to 508 more)	⨁◯◯◯ VERY LOW	CRITICAL
Maternal adverse effects – naproxen 275 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	5/30 (16.7%)	2/15 (13.3%)	**RR 1.25** (0.27 to 5.70)	**33 more per 1000** (from 97 fewer to 627 more)	⨁◯◯◯ VERY LOW	CRITICAL
Maternal adverse effects – naproxen 300 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	9/35 (25.7%)	5/17 (29.4%)	**RR 0.87** (0.35 to 2.21)	**38 fewer per 1000** (from 191 fewer to 356 more)	⨁◯◯◯ VERY LOW	CRITICAL
Maternal adverse effects – naproxen 550 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	8/30 (26.7%)	4/30 (13.3%)	**RR 2.00** (0.67 to 5.94)	**133 more per 1000** (from 44 fewer to 659 more)	⨁◯◯◯ VERY LOW	CRITICAL
Maternal adverse effects – naproxen 600 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	9/35 (25.7%)	5/18 (27.8%)	**RR 0.93** (0.36 to 2.36)	**19 fewer per 1000** (from 178 fewer to 378 more)	⨁◯◯◯ VERY LOW	CRITICAL

Certainty assessment							№ of patients		Effect		Certainty (GRADE)	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	NSAIDs	Placebo	Relative (95% CI)	Absolute (95% CI)		
Maternal adverse effects – ketorolac 5 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	6/30 (20.0%)	2/10 (20.0%)	**RR 1.00** (0.24 to 4.18)	**0 fewer per 1000** (from 152 fewer to 636 more)	⊕◯◯◯ VERY LOW	CRITICAL
Maternal adverse effects – ketorolac 10 mg												
1	randomized trials	serious [a]	not serious	serious [b]	very serious [c,f]	none	7/30 (23.3%)	2/10 (20.0%)	**RR 1.17** (0.29 to 4.73)	**34 more per 1000** (from 142 fewer to 746 more)	⊕◯◯◯ VERY LOW	CRITICAL
Maternal adverse effects – fenoprofen 200 mg												
1	randomized trials	serious [a]	not serious	not serious	very serious [c,f]	none	6/12 (50.0%)	5/12 (41.7%)	**RR 1.20** (0.50 to 2.88)	**83 more per 1000** (from 208 fewer to 783 more)	⊕◯◯◯ VERY LOW	CRITICAL

CI: confidence interval; RR: risk ratio.
a. The pooled effect provided by study "B".
b. Exclusion: breastfeeding women.
c. Wide confidence interval crossing the line of no effect.
d. Less than 300 women.
e. Wide confidence interval including the line of no effect.
f. Less than 300 women and 30 events.
g. Less than 30 events.